Alison Bentley Higgins
Corporate Officer/Principal chez Apitope Technology (Bristol) Ltd.
Profil
Alison Bentley Higgins is currently the Director of Quality Assurance at Apitope Technology (Bristol) Ltd.
She previously held positions as Director of Business Operations at Holzworth Holdings, Director of Quality Assurance at Apitope International NV, Vice President of Clinical Research at Janssen-Cilag International NV, and Principal at NHS AG and Quintiles UK Ltd.
Postes actifs de Alison Bentley Higgins
| Sociétés | Poste | Début |
|---|---|---|
Apitope Technology (Bristol) Ltd.
 Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Corporate Officer/Principal | 01/06/2010 |
Anciens postes connus de Alison Bentley Higgins
| Sociétés | Poste | Fin |
|---|---|---|
Apitope International NV
 Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Corporate Officer/Principal | - |
Holzworth Holdings, Inc.
 Holzworth Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Holzworth Holdings, Inc. conducts health research and provides technical, professional, and consulting services. The company was founded on December 19, 1996 and is headquartered in Durham, NC. | Directeur des opérations | - |
NHS AG
 NHS AG Advertising/Marketing ServicesCommercial Services NHS AG is an advertising agency. | Corporate Officer/Principal | - |
Janssen-Cilag International NV
 Janssen-Cilag International NV BiotechnologyHealth Technology Part of Johnson & Johnson, Janssen-Cilag International NV is a Belgian company that develops novel medicines and solutions. Bart Willem van Zijll Langhout has been the CEO of the company since 2009. | Directeur Technique/Scientifique/R&D | - |
| Quintiles UK Ltd. | Corporate Officer/Principal | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Janssen-Cilag International NV
Janssen-Cilag International NV BiotechnologyHealth Technology Part of Johnson & Johnson, Janssen-Cilag International NV is a Belgian company that develops novel medicines and solutions. Bart Willem van Zijll Langhout has been the CEO of the company since 2009. | Health Technology |
Holzworth Holdings, Inc.
Holzworth Holdings, Inc. Miscellaneous Commercial ServicesCommercial Services Holzworth Holdings, Inc. conducts health research and provides technical, professional, and consulting services. The company was founded on December 19, 1996 and is headquartered in Durham, NC. | Commercial Services |
NHS AG
NHS AG Advertising/Marketing ServicesCommercial Services NHS AG is an advertising agency. | Commercial Services |
| Quintiles UK Ltd. | |
Apitope International NV
Apitope International NV BiotechnologyHealth Technology Apitope International NV develops therapeutic vaccines. It operates as a bio-pharmaceutical company that engages in developing peptide therapies. The firm specializes on the discovery and development of revolutionary disease modifying therapies for treating autoimmune and allergic diseases, including multiple sclerosis, and Graves’ disease, FVIII intolerance and uveitis. The company was founded by David Wraith in 2002 and is headquartered in Diepenbeek, Belgium. | Health Technology |
Apitope Technology (Bristol) Ltd.
Apitope Technology (Bristol) Ltd. Miscellaneous Commercial ServicesCommercial Services Apitope Technology (Bristol) Ltd. is a European biotech company developing therapeutic vaccines for treating autoimmune and allergic diseases, including multiple sclerosis, Type 1 diabetes, Graves' disease, allergies and organ transplant rejection. The team at Apitope is developing potential therapies intended to selectively treat the underlying cause of a range of autoimmune diseases rather than simply treat the disease symptoms or non-specifically suppress the whole immune system. Apitope's approach is based on well-established scientific evidence published in leading scientific journals showing that soluble, synthetic peptides can selectively suppress abnormal immune responses and reinstate the normal immune balance and thereby, tolerance. The firm's strategy is to position itself as a significant player in the therapeutic peptide space and make it a partner of choice for pharmaceutical companies keen to develop disease modifiers for autoimmune conditions. It has a highly experienced senior management team, with a proven track record in discovering and developing innovative compounds. The company's lead product candidate is under investigation for the potential treatment of multiple sclerosis and is currently in Phase I clinical development. It is partnered with Merck-Serono (a division of Merck KGaA, Darmstadt, Germany), one of the leading companies in the development and marketing of MS therapies. | Commercial Services |
